1. A method of treating inflammation, comprising administering to a subject a pharmaceutically active serelaxin at a dose effective to induce transient up-regulation of soluble ST-2 in the tissue of said subject affected by inflammation, wherein said transient up-regulation of soluble ST-2 reduces the level of pro-inflammatory cytokines in said tissue. 2. The method of claim 1, wherein said pro-inflammatory cytokines are induced by IL-33.3. A method according to claim 1, characterized in that said tissue is selected from the group consisting of lung tissue, skin tissue, articular tissue, nervous tissue and vascular tissue. A method according to claim 1, characterized in that said dose of the pharmaceutically active serelaxin varies from about 10 μg / kg / day to about 500 μg / kg / day. The method of claim 1, wherein said inflammation comprises an inflammatory disease selected from the group consisting of eosinophilic hypersensitivity of the respiratory tract, asthma, rheumatoid arthritis, multiple sclerosis (MS (MS)), ankylosing spondylitis (AS (AS)), inflammatory bowel disease, gout, myositis, Sjogren's syndrome, systemic lupus erythematosus (SLE), vasculitis, malignant pleural disease, sepsis, trauma, wound healing, atopic allergy, anaphylaxis, autoimmune encephalomyelitis, hyp central nervous system oxia, vascular damage to the central nervous system, hypernociception, eczema, dermatitis, scleroderma, poisoning caused by rooting sumac, acne, the effects of bee stings and psoriasis. 6. A method according to claim 1, characterized in that said temporary positive regulation of soluble ST-2 lasts from about 1 day to about 5 days. The method according to p. 1, characterized1. Способ лечения воспаления, включающий введение субъекту фармацевтически активного серелаксина в дозе, эффективной для индукции временной положительной регуляции растворимого ST-2 в ткани указанного субъекта, пораженной воспалением, где указанная временная положительная регуляция растворимого ST-
